Plerixafor (AMD3100) 8HCl

Catalog No.S3013 Synonyms: JM 3100 8HCl,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride

For research use only.

Plerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.

Plerixafor (AMD3100) 8HCl Chemical Structure

CAS No. 155148-31-5

Selleck's Plerixafor (AMD3100) 8HCl has been cited by 39 publications

Purity & Quality Control

Choose Selective CXCR Inhibitors

Other CXCR Products

Biological Activity

Description Plerixafor (AMD3100, JM 3100,Plerixafor Octahydrochloride,AMD3100 octahydrochloride,SID791 octahydrochloride) 8HCl is the hydrochloride of Plerixafor, a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM in cell-free assays, respectively. Plerixafor can be used as an anti-HIV agent.
Targets
CXCL12 [1]
(Cell-free assay)
CXCR4 [1]
(Cell-free assay)
5.7 nM 44 nM
In vitro

Plerixafor inhibits CXCL12-mediated chemotaxis with a potency lightly better than its affinity for CXCR4. [1] Plerixafor also antagonizes SDF-1/CXCL12 ligand binding with an IC50 of 651 nM. Plerixafor inhibits SDF-1 mediated GTP-binding, SDF-1 mediated calcium flux and SDF-1 stimulated chemotaxis with IC50 of 27 nM, 572 nM and 51 nM, respectively. Plerixafor does not inhibit calcium flux against cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5 or CCR7 when stimulated with their cognate ligands, nor does Plerixafor inhibit receptor binding of LTB4. Plerixafor does not, on its own, induce a calcium flux in the CCRF–CEM cells, which express multiple GPCRs including CXCR4, CCR4 and CCR7. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CHOK1 cells MYLGeY5kfGmxbjDhd5NigQ>? NYLKSmNUTGm|cHzhZ4Vu\W62IH;mJHsyOjWLXWPESlFidHCqYTDmdo9uKEO[Q2K0JIV5eHKnc4Pl[EBqdiCFSF;LNUBk\WyuczygTWM2OD1yLkixJI5O NY\xXlR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe3NVUyOjhpPkG3O|E2OTJ6PD;hQi=>
GHOST CXCR4 cell line MXPGeY5kfGmxbjDhd5NigQ>? MV7Jcohq[mm2b4L5JINwdmOnboTyZZRqd25ib3[gZ49ueG:3bnSgZYdicW6|dDDITXYuOSCOQVmgd5Rz[WmwIHnuJGdJV1OWIFPYR3I1KGOnbHygcIlv\SxiSVO1NF0xNjl3IH7N NFr0fFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE5QSd-MUS2PVgyQDl:L3G+
HEK293 cells NVvPfotjTnWwY4Tpc44h[XO|YYm= MmDoNkBl[Xm| MnrDRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgWFIxNXKnc3nzeIFvfCCKSW[xJG5NPC1|IHnu[oVkfGWmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKH[rcnHsJJJmeGyrY3H0bY9vKGGodHXyJFIh\GG7czygTWM2OD1{LkOgcm0> NXjQS5Y1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OVE{ODVpPkG5OFUyOzB3PD;hQi=>
PBMC cells MnrwSpVv[3Srb36gZZN{[Xl? MUHF[oZm[3SrdnWgZ49v[2WwdILheIlwdiCxZjDjc41xd3WwZDDh[4FqdnO2IFjJWk0yKDh7Lk[gd5Rz[WmwIHnuJHBDVUNiY3XscJMtKEWFNUC9N{45KG6P NGGxSo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE5QSd-MUS2PVgyQDl:L3G+
human MT4 cells NWLjZVhITnWwY4Tpc44h[XO|YYm= NULrSldJPCCmYYnz MUTBcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKDOEIHnu[oVkfGWmIHnuJIh2dWGwIF3UOEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oII\pdpV{KHKncHzpZ4F1cW:wIHHmeIVzKDRiZHH5d{BjgSCPVGSgZZN{[XluIFXDOVA:PCCwTR?= M1zOWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMESzOlM5Lz5{MEC0N|Y{QDxxYU6=
human Jurkat cells MlqySpVv[3Srb36gZZN{[Xl? MV7BcpRi\2:waYP0JIFkfGm4aYT5JIF1KEO[Q2K0JIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOGRkGtbY5lfWOnZDDj[YxtKG2rZ4LheIlwdixiSVO1NF0zPy52IH7N NVTJWGF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxPFgxPzFpPkG5NVg5ODdzPD;hQi=>
MT-4 cells MYnGeY5kfGmxbjDhd5NigQ>? NVL2[3BCTW[oZXP0bZZmKGOxbnPlcpRz[XSrb36gc4Yh[2:vcH;1coQh[WejaX7zeEBJUVZvMTDJTWlDKHO2cnHpckBqdiCPVD20JINmdGy|LDDFR|UxRTZ3IH7N MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPDZ7OEG4PUc,OTR4OUixPFk9N2F-
rat IR983F cells M37MfmZ2dmO2aX;uJIF{e2G7 M1;3fmRqe3CuYXPlcYVvfCCxZjDbNVI2UV2FWFPMNVIh\nKxbTDDXGNTPCCrbjDyZZQhUVJ7OEPGJINmdGy|LDDJR|UxRTFyODDuUS=> M{\4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEWzO|Y5Lz5zOUC1N|c3QDxxYU6=
CEM-SS cells MlPWSpVv[3Srb36gZZN{[Xl? NGnGTmNG\m[nY4TpeoUh[2:wY3XueJJifGmxbjDv[kBkd22yb4Xu[EBi\2GrboP0JGhKXi1zIFzBTUB{fHKjaX6gbY4hS0WPLWPTJINmdGy|LDDFR|UxRTF{NzDuUS=> NFvmfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[5PFE5QSd-MUS2PVgyQDl:L3G+
human HL60 cells MWjGeY5kfGmxbjDhd5NigQ>? MmjTSIl{eGyjY3Xt[Y51KG:oIGuxNlVKZVOGRkHhcJBp[SCocn;tJGNZS1J2IHnuJIh2dWGwIFjMOlAh[2WubIOsJGlEPTB;MUWuNkDPxE1? MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF6OEC3NUc,OTlzOEiwO|E9N2F-
human MOLT4 cells M{W1TmZ2dmO2aX;uJIF{e2G7 NHzzUpAyODByIH7N MWXJcohq[mm2aX;uJI9nKE2jYjCxNmc2KGKrbnTpcochfG9iQ2jDVlQh\XiycnXzd4VlKGmwIHj1cYFvKE2RTGS0JINmdGy|IHH0JFExODBibl2gZpkhTkGFUzDhcoFtgXOrcx?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR3MUOwOUc,OTl2NUGzNFU9N2F-
human MT2 cells M3iweGZ2dmO2aX;uJIF{e2G7 NF\OenAyKHWpL33M NWrRb2pQPCCmYYnz M3PkZ2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiM1KgbY5n\WO2ZXSgbY4hcHWvYX6gUXQzKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicEK0JIFvfGmpZX6gdJJw\HWldHnvckBifCBzIIXnM41NKGGodHXyJFQh\GG7czDifUBGVEmVQR?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF4OEOzOkc,OjFzNkizN|Y9N2F-
human U87 cells M{fZWmZ2dmO2aX;uJIF{e2G7 MojGNVAxOCCwTR?= MYXBcpRi\2:waYP0JIFkfGm4aYT5JIF1KEO[Q2K0JIlvKGi3bXHuJHU5PyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHNFTjFvaX7keYNm\CCvb3T1cIF1cW:wIH;mJINCVVBicILv[JVkfGmxbjDheEAyODByIH7NJIJ6KFSULV\SSXQh[XO|YYm= NVS4R4FHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5OVg{PDRpPkG3PVU5OzR2PD;hQi=>
MT4 MXrBcpRqfmm{YXygZZN{[Xl? NWXBc3lsSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTCzRkBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ5l1d3CjdHjpZ{Bm\m[nY4SgbY4hVVR2IHPlcIx{NCCHQ{WwQVAvODFzzszN M4T2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5MEO0NVIzLz5zN{CzOFEzOjxxYU6=
U87 Moj1SpVv[3Srb36gZZN{[Xl? MnvnNVUhdWmwcx?= NH3wO3lCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IHj1cYFvKEO[Q2K0JIV5eHKnc4Pl[EBqdiCqdX3hckBWQDdiY3XscJMh\XiycnXzd4lv\yCFRESgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDDXGNNOTJvaX7keYNm\CClQV3QJJBzd2S3Y4Tpc44heHKndILlZZRm\CCob4KgNVUhdWmwczDi[YZwemViZn;yd4twdGmwIHPoZYxt\W6pZTDifUBVWi2IUlXUJIFv[Wy7c3nzMEBKSzVyPUCuOlk2|ryP NX2zVohXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxNFU4OTVpPkKxNVA2PzF3PD;hQi=>
MT4 M3XDeGFvfGm4aYLhcEBie3OjeR?= NUPhUok4SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhYDRvdILvdIlkKEiLVkGgUmw1NjNiaX7m[YN1\WRiaX6gbJVu[W5iTWS0JINmdGy|IHHzd4V{e2WmIHHzJJBzd3SnY4Tpc44h\nKxbTD2bZJ2ey2rbnT1Z4VlKGO7dH;wZZRpd2enbnnjbZR6NCCHQ{WwQVAvODZ{zszN MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV5OUSxPEc,OjJ3N{m0NVg9N2F-
MT4 NX22b3lsSW62aY\pdoFtKGG|c3H5 NFz2PZU2KGSjeYO= NW\PNo16SW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUEmYMTDpcoZm[3SnZDDpckBOXDRiY3XscJMh\XiycnXzd4lv\yCFWFPSOEBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJZqenW|LXnu[JVk\WRiY4n0c5BifGirYzDl[oZm[3RiYX\0[ZIhPSCmYYnzMEBGSzVyPUCuNFAz|ryP MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjlyOUC4PEc,OjJ7MEmwPFg9N2F-
CHO NIXFOnJHfW6ldHnvckBie3OjeR?= M1uxW2JqdmSrbnegZYZncW6rdImgeI8hcHWvYX6gdoVkd22kaX7hcpQhS1iFUkSg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiS3K9NE4xPzgQvF2= M3LqWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUC5NFg5Lz5{MkmwPVA5QDxxYU6=
CHO MXHGeY5kfGmxbjDhd5NigQ>? MX\BcpRi\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJJJm[2:vYnnuZY51KEO[Q2K0JIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCVRF[xZU1qdmS3Y3XkJIVt\WO2cnnjZYwhcW2yZXThcoNmKGK7IHTp[Yxm[3S{aXOgd5Bm[3S{b4Pjc5Bq[yCjbnHsfZNqeyxiSVO1NF0xNjJ4zszN NIeyeJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmwPVA5QCd-MkK5NFkxQDh:L3G+
CD44null NV3KUHpFTnWwY4Tpc44h[XO|YYm= MXK3JIRigXN? Mn3xSYZn\WO2IH;uJIh2dWGwIFfCUVIh[2WubDDkbYZn\XKnboTpZZRqd25iYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hS0R2NH71cIwh[2WubIOgZYZ1\XJiNzDkZZl{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>? M37yZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUC5NFg5Lz5{MkmwPVA5QDxxYU6=
CD44null M3jhdGZ2dmO2aX;uJIF{e2G7 NULEWGExPyCmYYnz NVL6RlBHTW[oZXP0JI9vKGi3bXHuJGdDVTFiY3XscEBlcW[oZYLlcpRq[XSrb36gZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iQ1S0OI52dGxiY3XscJMh[W[2ZYKgO{Bl[Xm|IHL5JIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?= NFHuVFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkmwPVA5QCd-MkK5NFkxQDh:L3G+
Assay
Methods Test Index PMID
Immunofluorescence CXCR4 ; β-arrestin2 28521261 31186083
In vivo

A single topical application of Plerixafor promotes wound healing in diabetic mice by increasing cytokine production, mobilizing bone marrow EPCs, and enhancing the activity of fibroblasts and monocytes/macrophages, thereby increasing both angiogenesis and vasculogenesis. [3] Cohorts of mice are administered with PBS, IGF1, PDGF, SCF, or VEGF for five consecutive days and Plerixafor on the 5th day. The number and size of the colonies are highest in IGF1 plus Plerixafor injected mice compared to PDGF, SCF and VEGF treated groups, in combination with Plerixafor. [4]

Protocol (from reference)

Animal Research:

[4]

  • Animal Models: Twelve-week-old C57BL/6 mice with segmental bone defect
  • Dosages: 5 mg/kg
  • Administration: Administered via i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.

30 mg/mL

Chemical Information

Molecular Weight 794.47
Formula

C28H54N8.8HCl

CAS No. 155148-31-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05421416 Not yet recruiting Drug: Loratadine|Drug: Placebo Stem Cell Transplant Complications AHS Cancer Control Alberta November 1 2022 Phase 2
NCT05343572 Not yet recruiting Drug: Plerixafor Asherman Syndrome|Atrophic Endometrium|Recurrent Implantation Failure Hugh Taylor|Yale University September 2022 Early Phase 1
NCT05411575 Active not recruiting Drug: Plerixafor 20 MG/ML [Mozobil]|Other: Placebo COVID-19 Acute Respiratory Distress Syndrome|COVID-19 4Living Biotech|4P-Pharma July 19 2022 Phase 2
NCT05445128 Recruiting Biological: MGTA-145|Drug: Plerixafor Sickle Cell Disease Magenta Therapeutics Inc.|bluebird bio June 24 2022 Phase 2
NCT04646603 Recruiting Drug: MRG-001|Drug: Placebo COVID-19|ARDS Human|Stem Cells|Regeneration MedRegen LLC|ICON plc|Johns Hopkins University December 1 2021 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-11-29)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Plerixafor (AMD3100) 8HCl | Plerixafor (AMD3100) 8HCl ic50 | Plerixafor (AMD3100) 8HCl price | Plerixafor (AMD3100) 8HCl cost | Plerixafor (AMD3100) 8HCl solubility dmso | Plerixafor (AMD3100) 8HCl purchase | Plerixafor (AMD3100) 8HCl manufacturer | Plerixafor (AMD3100) 8HCl research buy | Plerixafor (AMD3100) 8HCl order | Plerixafor (AMD3100) 8HCl mouse | Plerixafor (AMD3100) 8HCl chemical structure | Plerixafor (AMD3100) 8HCl mw | Plerixafor (AMD3100) 8HCl molecular weight | Plerixafor (AMD3100) 8HCl datasheet | Plerixafor (AMD3100) 8HCl supplier | Plerixafor (AMD3100) 8HCl in vitro | Plerixafor (AMD3100) 8HCl cell line | Plerixafor (AMD3100) 8HCl concentration | Plerixafor (AMD3100) 8HCl nmr